论文部分内容阅读
目的 :评价支气管动脉导管化疗 (简称动脉化疗 )联合雾化吸入IL— 2与同期单用动脉化疗治疗晚期非小细胞肺癌 (NSCLC)的疗效。方法 :41例晚期肺癌病人分成两组 ,治疗组 2 1例 ,在采用环磷酰胺、阿霉素、顺铂动脉灌注化疗的同时雾化吸入IL— 2 ;对照组 2 0例单用动脉化疗。两组动脉化疗用药情况和剂量相同。结果 :治疗组总有效率为 76 .19% ,初治总有效率为 83.3% ,复治总有效率为 33 .3 % ;对照组总有效率为 45 .0 0 % ,初治总有效率为 5 3.3% ,复治总有效率 2 0 %。两组总有效率经统计学处理有差异 (P <0 .0 5 )。结论 :动脉化疗联合雾化吸入IL— 2治疗晚期NSCLC ,疗效明显优于单用动脉化疗 ,初治疗效较复治效果显著
Objective: To evaluate the efficacy of bronchial artery catheterization chemotherapy (abbreviated as arterial chemotherapy) combined with nebulized IL-2 and concurrent arterial chemotherapy alone in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Forty-one patients with advanced lung cancer were divided into two groups. The treatment group consisted of 21 patients. Inhalation of IL-2 was induced by cyclophosphamide, doxorubicin, and cisplatin arterial infusion chemotherapy. In the control group, 20 patients received arterial chemotherapy alone. . The conditions and doses of arterial chemotherapy were the same in both groups. Results: The total effective rate was 76.19% in the treatment group, the total effective rate was 83.3% in the initial treatment, the total effective rate was 33.3% in the retreatment, and the total effective rate was 45.00% in the control group. The initial treatment total efficiency For 3.3%, the total effective rate of retreatment is 20%. The total effective rate of the two groups was statistically different (P < 0.05). Conclusion: Arterial chemotherapy combined with aerosol inhalation of IL-2 in the treatment of advanced NSCLC is obviously superior to arterial chemotherapy alone. The initial treatment effect is more effective than that of retreatment.